274 related articles for article (PubMed ID: 15548779)
1. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
Fischer MA; Schneeweiss S; Avorn J; Solomon DH
N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
[TBL] [Abstract][Full Text] [Related]
2. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
[TBL] [Abstract][Full Text] [Related]
3. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.
Smalley WE; Griffin MR; Fought RL; Sullivan L; Ray WA
N Engl J Med; 1995 Jun; 332(24):1612-7. PubMed ID: 7753141
[TBL] [Abstract][Full Text] [Related]
4. Prior-authorization programs for controlling drug spending.
Hamel MB; Epstein AM
N Engl J Med; 2004 Nov; 351(21):2156-8. PubMed ID: 15548775
[No Abstract] [Full Text] [Related]
5. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population.
Hartung DM; Touchette DR; Ketchum KL; Haxby DG; Goldberg BW
Clin Ther; 2004 Sep; 26(9):1518-32. PubMed ID: 15531015
[TBL] [Abstract][Full Text] [Related]
6. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
8. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
Shireman TI; Rigler SK
Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors.
Roughead EE; Zhang F; Ross-Degnan D; Soumerai S
Med Care; 2006 Apr; 44(4):378-82. PubMed ID: 16565640
[TBL] [Abstract][Full Text] [Related]
10. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
12. Medicaid prior authorization and controlled-release oxycodone.
Morden NE; Zerzan JT; Rue TC; Heagerty PJ; Roughead EE; Soumerai SB; Ross-Degnan D; Sullivan SD
Med Care; 2008 Jun; 46(6):573-80. PubMed ID: 18520311
[TBL] [Abstract][Full Text] [Related]
13. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Lelorier J
J Rheumatol; 2006 Mar; 33(3):588-96. PubMed ID: 16463432
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska.
Siracuse MV; Vuchetich PJ
Health Serv Res; 2008 Feb; 43(1 Pt 2):435-50. PubMed ID: 18199195
[TBL] [Abstract][Full Text] [Related]
15. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
[TBL] [Abstract][Full Text] [Related]
16. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
17. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
Patino FG; Allison J; Olivieri J; Mudano A; Juarez L; Person S; Mikuls TR; Moreland L; Kovac SH; Saag KG
Arthritis Rheum; 2003 Jun; 49(3):293-9. PubMed ID: 12794782
[TBL] [Abstract][Full Text] [Related]
18. Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous.
Roumie CL; Arbogast PG; Mitchel EF; Griffin MR
J Gen Intern Med; 2005 Oct; 20(10):879-83. PubMed ID: 16191131
[TBL] [Abstract][Full Text] [Related]
19. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?
Fischer MA; Choudhry NK; Winkelmayer WC
Health Aff (Millwood); 2007; 26(3):800-7. PubMed ID: 17485759
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
